Published: Tuesday, April 20, 2021 7:01 PM
The Public Health Commission decided not to change the timelines for the administration of the second dose of the Pfizer and Moderna vaccines, a proposal that was considered to try to increase the first dose vaccination for vulnerable groups.
According to the Executive, by delaying the inoculation of the second dose, it would be possible to advance in the vaccination of priority sectors. Something that countries like UK, France, Italy, Finland, Germany or Denmark are already in the process of launching. But, as the Minister of Health, Carolina Darias, confirmed during her appearance at the Senate Committee on Health and Consumption, it was finally agreed not to change anything on the doses: “I am happy that the current interval continues because it is more advantageous. I agree that the dose interval remains as is, ”said the Minister.
In this sense, Darias considered that the protocol already established to administer the two doses is one of the “certainties” that we have in the vaccination strategy. Currently, the second injection of Moderna’s vaccine is given at 28 days and for that of Pfizer, a margin of 21 days has been established, following the recommendations in the drug data sheet.
Various options were raised on the table. The first, to continue with the same separation between the first and second doses with the mRNA vaccines, following the strategy; the second, to increase the separation interval from six to eight weeks in people under 79 years of age; and the last, by increasing the time between doses for people under 69 years of age over a period of six to eight weeks.
But the European Medicines Agency (EMA) had previously warned that second doses of these formulas should not be delayed beyond the designated days. And it is that they emphasize that it is only by respecting the deadlines that the effectiveness that the vaccine has recorded in clinical trials is guaranteed. “Currently, there are no clinical data on the effectiveness of the vaccine when administered beyond the intervals used in the clinical trial,” warned the European regulator.